Search Results

Viewing Page 1 of 10 | Showing results 1 - 10 of 96

A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY) (AIN457A2326)

Participants are needed for this UC Irvine Health clinical study of secukinumab efficiacy in moderate to severe plaque psoriasis.
Natasha Mesinkovska, MD, PhD

UC Irvine Dermatology Clinical Research Center, 1001 Hewitt Hall, Irvine, CA 92697

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)

Participants are needed for this research study that will evaluate an investigational therapy that hopes to improve motor function after a...
Steven Cramer, MD

Study visits will take place at Hewitt Hall on the UC Irvine campus and at UC Irvine Medical Center in Orange. The surgery will take place at UC Irvine Medical Center.

Open